Loading clinical trials...
Loading clinical trials...
A Non-interventional Biomarker Study in Patients With Non-Small Cell Lung Cancer (NSCLC) of Adenocarcinoma Tumour Histology Eligible for Treatment With Vargatef® According to the Approved Label.
Conditions
Locations
71
Austria
LK Krems
Krems, Austria
AKH - Medical University of Vienna
Vienna, Austria
Brussels - UNIV Saint-Luc
Brussels, Belgium
AZ Maria Middelares
Ghent, Belgium
AZ Sint-Lucas - Campus Sint Lucas
Ghent, Belgium
Ieper - HOSP Jan Yperman
Ieper, Belgium
Start Date
March 9, 2016
Primary Completion Date
September 3, 2019
Completion Date
September 3, 2019
Last Updated
September 24, 2020
NCT06667908
NCT04165798
NCT06875310
NCT07046923
NCT07222566
NCT06667076
Lead Sponsor
Boehringer Ingelheim
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions